In the treat CTC trial, patients with non-metastatic disease and the presence of HER2 non-amplified primary tumors that have at least one CTC by analysis of 15 mL of blood (two tubes) are treated with HER2 antibody therapy (Trastuzumab, CTC arm). Here, ERBB2 is linked to metastatic neoplasm.